
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
In adults being treated for
This is one of 7 recommendations on the detection and management of white coat and masked hypertension made in the landmark
In this brief slide show for primary care practitioners, we summarize all 7 recommendations as well as the evidence in support of each.






